Research Communications of the 27(th) ECVIM-CA Congress: Intercontinental, Saint Julian's, Malta, 14th to 16th September 2017

Six cats were enrolled. The first three cats received 5 µg/kg q24 h PO and the second three cats received 10 ug/kg q24 h PO of cabergoline. The median IGF-1 concentration at day 0 was 1797 ng/mL (range 890->2000) which was not statistically different to day 4 and month 1 (1884 ng/mL and 1754 ng/mL, respectively). The median fructosamine concentration on day 0 was 551 lmol/L (range 454-887) which was not statistically different from day 4 and month 1 (551 to 569, respectively). All cats were receiving PZI insulin (ProZinc, Boehringer) and the median dose on day 0 (1.1 units/kg q12 h) was not different to day 4 and month 1 (1.1 and 1.2, respectively). Three patients experienced a single gastrointestinal upset event (inappetence, diarrhea) which resolved within three days. One of the six cats experienced an improvement of diabetic control (fructosamine day 0 was 454 lmol/L and month 1 was 288 lmol/L while insulin dose on day 0 was 1 unit/kg q12 h and month 1 was 0.2 units/kg q12 h) although there was no decrease of IGF-1 concentration (day 0: 890 ng/mL; month 1: 929 ng/mL).